Multiple Sclerosis New Zealand is aware that your DHB has been presented with a Business Case to make autologous haematopoietic stem cell transplants (aHSCT) available in your DHB to patients with Multiple Sclerosis. Multiple Sclerosis New Zealand requests a copy of this Business Case along with further information including any analysis of the business case correspondence etc regarding your decisions on this application.
Showing 1-5 of 5 results, page 1 of 1.
Page last updated: 16 September 2021
Is this page useful?